Listar DBCFI-Artículos, capítulos... por autor "384831dd-e0d8-4bdc-a6fd-8349cf8f7423"
Mostrando ítems 1-2 de 2
-
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, Sandra; Morgado-Pascual, José Luis; Opazo-Ríos, Lucas; Guerrero-Hue, Melania; García-Caballero, Cristina; Vázquez-Carballo, Cristina; Mas, Sebastián; Sanz, Ana Belén; Herencia, Carmen; Mezzano, Sergio; Gómez-Guerrero, Carmen; Moreno, Juan Antonio; Egido, J. (MDPI, 2020)Diabetic nephropathy (DN) is associated with an increased morbidity and mortality, resulting in elevated cost for public health systems. DN is the main cause of chronic kidney disease (CKD) and its incidence increases the ... -
Semaglutide improves liver steatosis and de novo lipogenesis markers in obese and type-2-diabetic mice with metabolic-dysfunction-associated steatotic liver disease
Soto-Catalán, Manuel; Opazo-Ríos, Lucas; Quiceno, Hernán; Lázaro, Iolanda; Moreno, Juan Antonio; Gómez-Guerrero, Carmen; Egido, J.; Mas-Fontao, Sebastián (MDPI, 2024)Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a prevalent clinical condition associated with elevated morbidity and mortality rates. Patients with MASLD treated with semaglutide, a glucagon-like ...